| Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions G Bauer, M Elsallab, M Abou-El-Enein Stem cells translational medicine 7 (9), 676-685, 2018 | 149 | 2018 |
| Scalable manufacturing of CAR T cells for cancer immunotherapy M Abou-el-Enein, M Elsallab, SA Feldman, AD Fesnak, HE Heslop, ... Blood cancer discovery 2 (5), 408-422, 2021 | 116 | 2021 |
| CAR T-cell product performance in haematological malignancies before and after marketing authorisation M Elsallab, BL Levine, AS Wayne, M Abou-El-Enein The Lancet Oncology 21 (2), e104-e116, 2020 | 68 | 2020 |
| Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals M Elsallab, CA Bravery, A Kurtz, M Abou-El-Enein Molecular Therapy-Methods & Clinical Development, 2020 | 43 | 2020 |
| Post-marketing safety and efficacy surveillance of cell and gene therapies in the EU: A critical review E Fritsche, M Elsallab, M Schaden, SP Hey, M Abou-El-Enein Cell Gene Ther. Insights 5 (11), 1505-21, 2019 | 19 | 2019 |
| Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis M Elsallab, M Ellithi, S Hempel, H Abdel-Azim, M Abou-el-Enein Cancer Gene Therapy 30 (6), 845-854, 2023 | 15 | 2023 |
| Detection of SARS‐CoV‐2‐specific memory B cells to delineate long‐term COVID‐19 immunity CJ Thieme, M Abou‐el‐Enein, E Fritsche, M Anft, K Paniskaki, ... Allergy 76 (8), 2595, 2021 | 9 | 2021 |
| Expanding access to CAR T cell therapies through local manufacturing M Elsallab, MV Maus Nature Biotechnology 41 (12), 1698-1708, 2023 | 4 | 2023 |
| Linking scattered stem cell-based data to advance therapeutic development A Kurtz, M Elsallab, R Sanzenbacher, M Abou-El-Enein Trends in Molecular Medicine 25 (1), 8-19, 2019 | 4 | 2019 |
| CAR NK-92 cell–mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products J Kath, W Du, S Martini, M Elsallab, C Franke, L Hartmann, V Drosdek, ... Blood Advances 7 (15), 4124-4134, 2023 | 3 | 2023 |
| Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS) M Elsallab, M Ellithi, MA Lunning, C D’Angelo, J Ma, MA Perales, ... Blood, 2024 | 1 | 2024 |
| Autologous Anti CD-19 Chimeric Antigen Receptor T cells in Relapsed or Refractory Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis. M Elsallab, M Ellithi, M Abou-el-Enein OSF, 2022 | 1 | 2022 |
| National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector Cells M Elsallab, F Bourgeois, MV Maus Transplantation and Cellular Therapy, 2024 | | 2024 |
| Detection of SARS-CoV-2 Specific Memory B cells to Delineate Long-Term COVID-19 Immunity (preprint) C Thieme, M Abou-el-Enein, E Fritsche, M Anft, S Skrzypczyk, M Elsallab, ... | | 2021 |
| Investigating and Guiding Evidence Generation to Inform Regulatory Decision-Making for Advanced Therapy Medicinal Products (ATMPs) M Elsallab | | 2021 |
Mohamed Abou-el-EneinKeck School of Medicine USCVerified email at med.usc.edu
